Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.56 |
| ▸ | CCR8 | P51685 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.39 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26521060 | 0.84 | CCR1 (0.60) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL26520751 | 0.81 | CCR1 (0.56) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL12968260 | 0.81 | CCR1 (0.56) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL3409467 | 0.79 | CCR1 (0.65) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL10032237 | 0.79 | CCR1 (0.59) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL26521057 | 0.77 | CCR1 (0.50) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL12968256 | 0.77 | TGFBR1 (0.38) | TGFBR1GRM5KDM4EMAPK14 | |
| SCHEMBL26521070 | 0.77 | CCR1 (0.50) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL14721128 | 0.76 | CCR1 (0.60) | CCR1CCR8CYP2A6METAP2TGFBR1 | |
| SCHEMBL16005733 | 0.75 | CCR1 (0.48) | CCR1CCR8CYP2A6TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604036-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| EP-2280962-B1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| CN-102015694-A | Pyridazinone derivatives | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2280962-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009129905-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, BRAF | CCR1 3947/4885CCR8 4673/4885CYP2A6 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.